1329159-64-9Relevant academic research and scientific papers
Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker
Corte, James R.,Fang, Tianan,Osuna, Honey,Pinto, Donald J. P.,Rossi, Karen A.,Myers, Joseph E.,Sheriff, Steven,Lou, Zhen,Zheng, Joanna J.,Harper, Timothy W.,Bozarth, Jeffrey M.,Wu, Yiming,Luettgen, Joseph M.,Seiffert, Dietmar A.,Decicco, Carl P.,Wexler, Ruth R.,Quan, Mimi L.
, p. 1060 - 1075 (2017)
A novel series of macrocyclic FXIa inhibitors was designed based on our lead acyclic phenyl imidazole chemotype. Our initial macrocycles, which were double-digit nanomolar FXIa inhibitors, were further optimized with assistance from utilization of structure-based drug design and ligand bound X-ray crystal structures. This effort resulted in the discovery of a macrocyclic amide linker which was found to form a key hydrogen bond with the carbonyl of Leu41 in the FXIa active site, resulting in potent FXIa inhibitors. The macrocyclic FXIa series, exemplified by compound 16, had a FXIa Ki = 0.16 nM with potent anticoagulant activity in an in vitro clotting assay (aPTT EC1.5x = 0.27 μM) and excellent selectivity against the relevant blood coagulation enzymes.
MACROCYCLES AS FACTOR XIA INHIBITORS
-
Page/Page column 177-178, (2011/09/15)
The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
